Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $33.00. Faisal Khurshid has given his Buy rating due ...
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback